Internationale Publikationen
Hier stellen wir eine Auswahl wissenschaftlicher Veröffentlichungen zur Verfügung, die im Zusammenhang mit der IOZK-Immuntherapie stehen.
Sie können mit Hilfe der Filter eine Auswahl nach Tumorarten und Methoden treffen, oder Suchbegriffe eingeben.
Dendritic cell vaccines in metastasized malignant melanoma
Regional hyperthermia of the abdomen in conjunction with chemotherapy for peritoneal carcinomatosis: evaluation of two annular-phased-array applicators
A two-state cell damage model under hyperthermic conditions: theory and in vitro experiments
A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas
Development of a dendritic cell-based vaccine for chronic lymphocytic leukemia
[Specific immune against pancreatic cancer induced by dendritic cells pulsed with mutant K-ras peptide]
Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients
TIMP-1-GPI in combination with hyperthermic treatment of melanoma increases sensitivity to FAS-mediated apoptosis
Inoperable Pancoast tumors treated with hyperthermia-inclusive multimodality therapies
Monocyte-derived dendritic cells from HCV-infected patients transduced with an adenovirus expressing NS3 are functional when stimulated with the TLR3 ligand poly(I:C)
Alterations in p53-specific T cells and other lymphocyte subsets in breast cancer patients during vaccination with p53-peptide loaded dendritic cells and low-dose interleukin-2
Maximizing dendritic cell migration in cancer immunotherapy
Strategies to overcome obstacles to successful immunotherapy of melanoma
Phase I/II study of treatment with matured dendritic cells with or without low dose IL-2 in patients with disseminated melanoma
Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor
IFN-producing killer dendritic cells contribute to the inhibitory effect of poly I:C on the progression of murine melanoma
Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma
Dendritic cell vaccination with xenogenic polypeptide hormone induces tumor rejection in neuroendocrine cancer
CD40ligand-expressing dendritic cells induce regression of hepatocellular carcinoma by activating innate and acquired immunity in vivo
Fusions of dendritic cells with breast carcinoma stimulate the expansion of regulatory T cells while concomitant exposure to IL-12, CpG oligodeoxynucleotides, and anti-CD3/CD28 promotes the expansion of activated tumor reactive cells